Northern India Herald

DelveInsight’s “Psoriasis Pipeline Insight, 2025” report provides comprehensive insights about 65+ companies and 75+ pipeline drugs in the Psoriasis pipeline landscape. It covers the Psoriasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Psoriasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Psoriasis Research. Learn more about our innovative pipeline today! @ Psoriasis Pipeline Outlook

Key Takeaways from the Psoriasis Pipeline Report

• In June 2025, Alumis Inc. announced a study following completion of one of the parent studies (ESK-001-016 or ESK-001-017) and will receive open-label ESK-001 twice daily for 24 weeks. After 24 weeks, the first 200 patients meeting at least PASI-75 clinical response will be randomly assigned to receive ESK-001 or placebo. At any point during this time, the patients losing the initial clinical response may return to the open-label ESK-001 treatment.
• In June 2025, Soligenix conducted a study to evaluate SGX302 (topical hypericin ointment and gel) with visible light in an initial 18-week treatment course for improving lesions in patients with mild-to-moderate psoriasis.
• In June 2025, Organon and Co. organized an open-label study in which participants will be assigned to receive VTAMA (tapinarof) cream, 1% once daily for 12 weeks. Study participants will have a follow-up period of 1 week. The study duration will be up to 17 weeks.
• DelveInsight’s Psoriasis pipeline report depicts a robust space with 65+ active players working to develop 75+ pipeline therapies for Psoriasis treatment.
• The leading Psoriasis Companies such as Can-Fite Biopharma, Huabo Biopharm Co., Ltd., MoonLake Immunotherapeutics, E-nitiate Biopharmaceuticals, Chia Tai Tianqing Pharmaceutical Group, BioRay Pharmaceutical Co., Ltd., SFA Therapeutics, Rubedo Life Sciences, Inc. and others.
• Promising Psoriasis Pipeline Therapies such as Hypericin, EDP1815, Cetaphil, AX-158, HAT1 topical solution, Calcipotriol, ARQ-151 cream 0.3%, MP1032, Risankizumab, Certolizumab Pegol, and others.

Stay informed about the cutting-edge advancements in Psoriasis treatments. Download for updates and be a part of the revolution in Immunological and Autoimmune Disorders care @ Psoriasis Clinical Trials Assessment

Psoriasis Emerging Drugs Profile

• Piclidenoson: Can-Fite Biopharma

Piclidenoson, generically known as IB-MECA (methyl 1-[N6-(3-iodobenzyl)-adenin-9-yl]-b-D-ribofuronamide), is an oral small molecule drug formulated in a tablet. Piclidenoson mechanism of action is A3AR mediated and includes modulation of key signaling proteins, such as PI3K, PKA, PKB/Akt, IKK and NF-kB, resulting in de-regulation of the Wnt/β-catenin pathway and inhibition of inflammatory cytokine production. Currently, the drug is in Phase III stage of its development for the treatment of Psoriasis. 

• Sonelokimab: MoonLake Immunotherapeutics

Sonelokimab is an investigational Nanobody® developed by MoonLake Immunotherapeutics for treating inflammatory diseases. It targets IL-17A and IL-17F cytokines, inhibiting the IL-17A/A, IL-17A/F, and IL-17F/F dimers, and includes a domain that binds to human albumin to enhance tissue penetration . In Phase 2 trials, sonelokimab demonstrated superior efficacy compared to AbbVie’s Humira in psoriatic arthritis, with higher percentages of patients achieving significant improvements in joint swelling and psoriasis severity . Additionally, it showed promising results in treating hidradenitis suppurativa, meeting the HiSCR75 endpoint in the Phase 2 MIRA trial. Currently, MoonLake is conducting Phase III trials for both conditions and exploring its use in other inflammatory diseases such as palmoplantar pustulosis and axial spondyloarthritis.

• QY101: E-nitiate Biopharmaceuticals

QY101 is a topical ointment developed by E-nitiate Biopharmaceuticals for treating inflammatory skin conditions like atopic dermatitis and plaque psoriasis. It functions as a non-steroidal, non-hormonal phosphodiesterase 4 (PDE4) inhibitor, aiming to reduce inflammation by targeting overactive PDE4 pathways. Preclinical studies have demonstrated favorable pharmacokinetics, strong efficacy, and high safety, making it suitable for various age groups, including children. Currently, QY101 is undergoing a Phase II clinical trial in China for plaque psoriasis, following the completion of a Phase I trial in healthy volunteers. The company is also exploring additional formulations, such as an inhaler, through licensing collaborations.

• SFA 002: SFA Therapeutics

SFA-002, an IL-10 up-regulator in immune cells, is approaching Phase 2 clinical trials and has shown promising Phase 1a and Phase Ib results for the treatment of psoriasis. SFA-002 met its primary endpoint of safety in the Phase 1b clinical trial. No treatment related adverse events or toxicities were observed during the treatment period, and no rebound effects were observed. SFA Therapeutics has filed its annual safety update with the U.S. Food and Drug Administration. SFA-002 met its exploratory endpoint of efficacy. Patients administered SFA-002 demonstrated statistically significant Psoriasis Area and Severity Index (PASI) percentage change and Investigator Global Assessment (IGA) score improvements compared to placebo. PASI is a tool used to measure the severity and extent of psoriasis while IGA is a standardized rating system of patient disease severity. The study was designed in two cohorts, to evaluate two different formulations. Currently the drug is in Phase II/III stage of its development for the treatment of Psoriasis.

• RLS-1496: Rubedo Life Sciences, Inc

RLS-1496 is a first-in-class GPX4 modulator that targets aging cells and surrounding tissues being developed by Rubedo Life Sciences for the treatment of dermatological conditions and other chronic age-related diseases. It is a topical medicine designed to target aging cells, specifically senescent cells, in skin lesions of chronic atopic dermatitis and chronic psoriasis. Currently the drug is in Preclinical stage of its development for the treatment of Psoriasis.

The Psoriasis Pipeline Report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Psoriasis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Psoriasis Treatment.
• Psoriasis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Psoriasis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Psoriasis market.

Learn more about Psoriasis Drugs opportunities in our groundbreaking Psoriasis research and development projects @ Psoriasis Unmet Needs

Psoriasis Companies

Can-Fite Biopharma, Huabo Biopharm Co., Ltd., MoonLake Immunotherapeutics, E-nitiate Biopharmaceuticals, Chia Tai Tianqing Pharmaceutical Group, BioRay Pharmaceutical Co., Ltd., SFA Therapeutics, Rubedo Life Sciences, Inc. and others.

Psoriasis Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Psoriasis Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide

Discover the latest advancements in Psoriasis treatment by visiting our website. Stay informed about how we’re transforming the future of Immunological and Autoimmune Disorders @ Psoriasis Market Drivers and Barriers, and Future Perspectives

Scope of the Psoriasis Pipeline Report

• Coverage- Global
• Psoriasis Companies- Can-Fite Biopharma, Huabo Biopharm Co., Ltd., MoonLake Immunotherapeutics, E-nitiate Biopharmaceuticals, Chia Tai Tianqing Pharmaceutical Group, BioRay Pharmaceutical Co., Ltd., SFA Therapeutics, Rubedo Life Sciences, Inc. and others.
• Psoriasis Pipeline Therapies- Hypericin, EDP1815, Cetaphil, AX-158, HAT1 topical solution, Calcipotriol, ARQ-151 cream 0.3%, MP1032, Risankizumab, Certolizumab Pegol, and others.
• Psoriasis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Psoriasis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Psoriasis Pipeline on our website @ Psoriasis Emerging Drugs and Companies

Table of Contents

1. Introduction
2. Executive Summary
3. Psoriasis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Psoriasis– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Piclidenoson: Can-Fite Biopharma
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II/III)
11. SFA 002: SFA Therapeutics
12. Early Stage Products (Phase I/II)
13. Drug Name: Company Name
14. Drug profiles in the detailed report…..
15. Preclinical and Discovery Stage Products
16. RLS-1496: Rubedo Life Sciences, Inc
17. Inactive Products
18. Psoriasis Key Companies
19. Psoriasis Key Products
20. Psoriasis- Unmet Needs
21. Psoriasis- Market Drivers and Barriers
22. Psoriasis- Future Perspectives and Conclusion
23. Psoriasis Analyst Views
24. Psoriasis Key Companies
25. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/psoriasis-pipeline-insight